Langues Français
Actifs pris en charge
NVAXc logo

Novavax

24/7

Ouvrir Mo

-

-sur la période sélectionnée

Dernière clôture
9,68 $US
Prime / décote
-
Mis à jour Référence Yahoo Finance ·

Écarts de prix avant frais et coûts d’exécution. Comparer les prix

Analyses

Investors weigh if Novavax's partnership royalty model can beat policy headwinds and reach profit, or if execution gaps and cash strain will halt progress.

Partner‑driven royalty and milestone execution

Partners such as Sanofi and Takeda are set to commercialize the XFG‑variant Nuvaxovid for the 2026‑2027 season, enabling Novavax to earn royalties and milestones without its own sales force.

Royalty and milestone flows could prove too small or lumpy, leaving Novavax exposed if partner sales or regulatory timing fall short.

Do Novavax’s (NVAX) New Partnerships Offset Policy Risks From The Protecting Approved Care Act?Why Novavax (NVAX) Is Up 10.4% After New XFG-Targeted Nuvaxovid Approvals Expand Partner-Led Reach - Simply Wall St NewsDo Novavax’s (NVAX) New Partnerships Offset Policy Risks From The Protecting Approved Care Act?Why Novavax (NVAX) Is Up 10.4% After New XFG-Targeted Nuvaxovid Approvals Expand Partner-Led Reach - Simply Wall St News

Impact of the Protecting Approved Care Act

The Protecting Approved Care Act focuses on Medicare Advantage mechanics and does not appear directly material to Novavax's current revenue drivers, limiting its policy impact.

Bipartisan lawmakers introduced the Protecting Approved Care Act, stirring concern across healthcare names like Novavax about potential changes to Medicare Advantage reimbursement practices.

Do Novavax’s (NVAX) New Partnerships Offset Policy Risks From The Protecting Approved Care Act?Do Novavax’s (NVAX) New Partnerships Offset Policy Risks From The Protecting Approved Care Act?Novavax (NVAX) Draws Focus On Policy Reform, Is It 34% Overvalued? - Simply Wall St News

Path to non‑GAAP profitability by 2028

Management targets non‑GAAP profitability by 2028 through expense reductions and a revenue mix shift toward high‑margin royalties, supported by $724M cash.

Novavax posted a $53.4 million Q2 2026 net loss and negative 59.87% profit margins, and relies on milestone payments before its $723.9 million cash runway exhausts.

Novavax's Matrix-M Pivot: The Catalysts Are Real, the Money Is Milestone-ShapedMatrix-M Platform Pivot: Can Novavax's Partnership Model Deliver Profits by 2028? (NASDAQ:NVAX) - NVAX Analysis - EveryTickerNovavax's Matrix-M Pivot: The Catalysts Are Real, the Money Is Milestone-ShapedMatrix-M Platform Pivot: Can Novavax's Partnership Model Deliver Profits by 2028? (NASDAQ:NVAX) - NVAX Analysis - EveryTicker

Actualités

Token

Token
NVAXc
Actions par token
1.00000000 NVAX
Contrat
0xb200000000000000000000c597c476fcf9aed3a8

Obtenir Mo

Conservez-le dans Mo

Conservez NVAXc dans un portefeuille intelligent Mo sur Base que vous contrôlez.

Déplacez-le vite

Envoyez NVAXc à un autre utilisateur Mo sans frais, ou vers tout portefeuille compatible Base de manière quasi instantanée.

Votre argent. Plus de possibilités.